Sanitary registration granted to Nasalferon for the treatment of acute respiratory infections

Havana, Mar 12.- The final approval of the drug Nasalferon, which is administered nasally and is easy for the population to use, was supported by the results of a phase III clinical study that demonstrated its antiviral effect, efficacy, and safety in controlling and improving the symptoms typical of these diseases.

The research, carried out during 2025 in health areas of Old Havana, had significant adherence to the protocol and confirmed the product's capacity for the complete resolution of respiratory symptoms, according to information provided by its developers.

According to CIGB, Nasalferon is a nasal drop formulation whose active ingredient is recombinant human interferon alpha 2b, a molecule that has been used in different pharmaceutical forms and various therapeutic niches.

The drug already had conditional sanitary registration for the prophylaxis of SARS-CoV-2 infection, the virus causing COVID-19, and now expands its indication to acute respiratory infections in general.

With this new registration, the medication is already in the process of being sold in community pharmacies, where the population can purchase it with a medical prescription, and its retail price was set at 172.50 CUP per 2 ml bottle.

As part of future projections, after proving safety and efficacy in the adult population, the CIGB work team plans to design new research to involve patients of pediatric ages, with the aim that the child population can also benefit from the use of this medication. With stable production by the Cuban biotechnology industry, Nasalferon is consolidated as another therapeutic alternative for acute respiratory diseases within reach of the population. (Text and photo: Granma Digital)